Basic Information
| LncRNA/CircRNA Name | CASC2 |
| Synonyms | NA |
| Region | GRCh38_10:118046279-118210153 |
| Ensemble | ENSG00000177640 |
| Refseq | NR_026939 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin? | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | oesophageal squamous cell carcinoma |
| ICD-0-3 | NA |
| Methods | qRT-PCR , Luciferase reporter assay , Western blot , in vitro knockdown etc. |
| Sample | human normal esophageal epithelial cell line Het-1A ,human ESCC cell lines(Eca109, KYSE140, KYSE150, TE-1, and EC9706) |
| Expression Pattern | down-regulated |
| Function Description | CASC2 was low-expressed in ESCC cell lines. Overexpression of CASC2 enhanced the inhibitory effect of cisplatin on cell viability and promoted cisplatin-induced LDH release and apoptosis.miR-181a expression levels were increased in ESCC cell lines. MiR-181a inhibitor enhanced the antitumor activity of cisplatin, which was similar with the effect of CASC2.CASC2 directly interacted with miR-181a and inhibited the miR-181a expression. MiR-181a reversed the effects of CASC2 on antitumor activity of cisplatin.CASC2 suppressed the Akt pathway by inhibiting miR-181a. |
| Pubmed ID | 31134151 |
| Year | 2019 |
| Title | Long Non-coding RNA CASC2 Enhances the Antitumor Activity of Cisplatin Through Suppressing the Akt Pathway by Inhibition of miR-181a in Esophageal Squamous Cell Carcinoma Cells |
External Links
| Links for CASC2 | GenBank HGNC NONCODE |
| Links for oesophageal squamous cell carcinoma | OMIM COSMIC |